Altimmune (Altimmune) Quality Rank

View and export this data going back to 2005. Start your Free Trial

What is Altimmune Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Altimmune Quality Rank Related Terms

Thank you for viewing the detailed overview of Altimmune's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Altimmune (Altimmune) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (NAS:ALT) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

ALT1:Mexico 3G0:Germany 3G0:Germany

Address

910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878

Website

https://www.altimmune.com

Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company's pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Executives

David Drutz	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Richard I Eisenstadt	officer: Chief Financial Officer	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Catherine A. Sohn	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Matthew Scott Harris	officer: Chief Medical Officer	C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Raymond M Jordt	officer: Chief Business Officer	ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Wayne Pisano	director	C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Vipin K Garg	director, officer: President and CEO	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John Gill	director	C/O PHARMATHENE, INC, ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
M Scot Roberts	officer: Chief Scientific Officer	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Diane Jorkasky	director	60 MANOR AVENUE, WELLESLEY MA 02482
Philip Hodges	director	19 FIRSTFIELD RD., SUITE 200, GAITHERSBURG MD 20878
Vhcp Management Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Ii, L.p.	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Co-investment Holdings Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018